SCHEMBL3247203

SCHEMBL3247203

[CH2]CCCCOC(C)CC

nearest known ligand 0.48

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
DNM1 Q05193 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3245017 0.98 DNM1 (0.33) DNM1
SCHEMBL3238394 0.98 DNM1 (0.33) DNM1
SCHEMBL3239330 0.98 DNM1 (0.33) DNM1
SCHEMBL5100755 0.98 DNM1 (0.33) DNM1
SCHEMBL20188 0.93
SCHEMBL16615645 0.87 DNM1 (0.36) DNM1
SCHEMBL16615781 0.87 DNM1 (0.36) DNM1
SCHEMBL20760 0.82
SCHEMBL2735119 0.82 LMNA (0.33) DNM1
SCHEMBL11411389 0.80 EPHX2 (0.39) DNM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023189817-A1 ONIUM SALT, ONIUM SALT COMPOSITION, LIQUID COMPOSITION CONTAINING ONIUM SALT AND POLYSACCHARIDE AND PRODUCTION METHOD THEREOF, AND METHOD FOR RECOVERING POLYSACCHARIDE 広栄化学株式会社 2023-10-05 WO disclosed
US-20210353555-A1 NANOPARTICLES BASED ON OPTIONALLY ALKOXYLATED POLY(ALKYL CYANOACRYLATES) HAVING A DEFINED DEGREE OF POLYMERIZATION AbbVie Deutschland GmbH & Co. KG (DE) 2021-11-18 US disclosed
EP-3377110-B1 NANOPARTICLES BASED ON OPTIONALLY ALKOXYLATED POLY(ALKYL CYANOACRYLATES) HAVING A DEFINED DEGREE OF POLYMERIZATION ABBVIE DEUTSCHLAND (DE) 2021-01-06 EP disclosed
US-20180325833-A1 NANOPARTICLES BASED ON OPTIONALLY ALKOXYLATED POLY(ALKYL CYANOACRYLATES) HAVING A DEFINED DEGREE OF POLYMERIZATION AbbVie Deutschland GmbH & Co. KG (DE) 2018-11-15 US disclosed
EP-3377110-A1 NANOPARTICLES BASED ON OPTIONALLY ALKOXYLATED POLY(ALKYL CYANOACRYLATES) HAVING A DEFINED DEGREE OF POLYMERIZATION AbbVie Deutschland GmbH & Co. KG (DE) 2018-09-26 EP disclosed
WO-2010069458-A1 HEXAHALOCHROMATE (LLL) COMPLEXES MERCK PATENT GMBH (DE) 2010-06-24 WO disclosed
US-7355053-B2 1-phenylpyrrolidine-2-one-3-carboxamides BASF AKTIENGESELLSCHAFT (DE) 2008-04-08 US disclosed
US-20060019831-A1 1-phenylpyrrolidine-2-one-3-carboxamides BASF AKTIENGESELLSCHAFT (DE) 2006-01-26 US disclosed
EP-1556346-A1 1-PHENYLPYRROLIDINE-2-ONE-3-CARBOXAMIDES BASF AKTIENGESELLSCHAFT (DE) 2005-07-27 EP disclosed
WO-2004037787-A1 1-PHENYLPYRROLIDINE-2-ONE-3-CARBOXAMIDES BASF AKTIENGESELLSCHAFT (DE) 2004-05-06 WO disclosed
EP-1140847-B1 SUBSTITUTED 2-PHENYLPYRIDINES AS HERBICIDES BASF AG (DE) 2002-12-18 EP disclosed
US-6448205-B1 FOR THE DESICCATION AND/OR DEFOLIATION OF PLANTS BASF AKTIENGESELLSCHAFT (DE) 2002-09-10 US disclosed
US-6448247-B1 TACHYKININ RECEPTOR ANTAGONIST; ESPECIALLY TO THE RECEPTORS FOR SUBSTANCE P (WHICH RECEPTORS ARE GENERALLY REFERRED TO AS ?NEUROKININ 1 RECEPTORS?) SANKYO COMPANY, LIMITED (JP) 2002-09-10 US disclosed
US-6432880-B1 APPLYING TO PLANTS BASF AKTIENGESELLSCHAFT (DE) 2002-08-13 US disclosed
CN-1336918-A Substituted 2-phenylpyridines as herbicides BASF AG (DE) 2002-02-20 CN disclosed
US-6159967-A Heterocyclic compounds having tachykinin receptor antagonist activity their preparation and their use SANKYO COMPANY, LIMITED (JP) 2000-12-12 US disclosed
CN-1157286-A N,N-dimethyl-1-t-butoxycarbonyl-4-phenylpiperidine-4-carboxamide SANKYO CO (JP) 1997-08-20 CN disclosed
EP-0776893-A1 Azaheterocyclic compounds having tachykinin receptor antagonist activity; Nk1 and NK2 SANKYO COMPANY LIMITED (JP) 1997-06-04 EP disclosed
US-4289883-A ADRENERGIC BLOCKING AGENTS OF EXCELLENT CARDIOSELECTIVITY OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1981-09-15 US disclosed
US-4210753-A TREATMENT OF CARDIAC DISORDERS AND CHRONIC LUNG DISEASE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1980-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180325833-A1 NANOPARTICLES BASED ON OPTIONALLY ALKOXYLATED POLY(ALKYL CYANOACRYLATES) HAVING A DEFINED DEGREE OF POLYMERIZATION CLTA, ACMSD, ALKBH3 DNM1 3826/4885
US-20060019831-A1 1-phenylpyrrolidine-2-one-3-carboxamides RXFP1, REN, NPY1R DNM1 1324/4885
US-20210353555-A1 NANOPARTICLES BASED ON OPTIONALLY ALKOXYLATED POLY(ALKYL CYANOACRYLATES) HAVING A DEFINED DEGREE OF POLYMERIZATION CLTA, ACMSD, ALKBH3 DNM1 3826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.